GB1582362A - Cromoglycic acid salts and compositions - Google Patents
Cromoglycic acid salts and compositions Download PDFInfo
- Publication number
- GB1582362A GB1582362A GB11390/77A GB1139077A GB1582362A GB 1582362 A GB1582362 A GB 1582362A GB 11390/77 A GB11390/77 A GB 11390/77A GB 1139077 A GB1139077 A GB 1139077A GB 1582362 A GB1582362 A GB 1582362A
- Authority
- GB
- United Kingdom
- Prior art keywords
- salt
- bis
- yloxy
- propan
- carboxychromon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical class [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 title 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 230000001387 anti-histamine Effects 0.000 claims abstract description 42
- 229940125715 antihistaminic agent Drugs 0.000 claims abstract description 11
- 150000007514 bases Chemical class 0.000 claims abstract description 6
- 239000000938 histamine H1 antagonist Substances 0.000 claims abstract description 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 229960000265 cromoglicic acid Drugs 0.000 claims description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 16
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 10
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 9
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical class C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims description 9
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical group C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 7
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 7
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229960001128 triprolidine Drugs 0.000 claims description 6
- 229960001593 triprolidine hydrochloride Drugs 0.000 claims description 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims description 4
- 229960003790 alimemazine Drugs 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000725 brompheniramine Drugs 0.000 claims description 4
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000428 carbinoxamine Drugs 0.000 claims description 4
- 229960003291 chlorphenamine Drugs 0.000 claims description 4
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001140 cyproheptadine Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000582 mepyramine Drugs 0.000 claims description 4
- 229960001190 pheniramine Drugs 0.000 claims description 4
- 239000000902 placebo Substances 0.000 claims description 4
- 229940068196 placebo Drugs 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 229960003223 tripelennamine Drugs 0.000 claims description 4
- 229960001992 dimetindene Drugs 0.000 claims description 3
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000003352 sequestering agent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- CBEQULMOCCWAQT-WQRHYEAKSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 CBEQULMOCCWAQT-WQRHYEAKSA-N 0.000 claims description 2
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 claims description 2
- 239000007832 Na2SO4 Substances 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000008364 bulk solution Substances 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- UNEXJVCWJSHFNN-UHFFFAOYSA-N n,n,n',n'-tetraethylmethanediamine Chemical compound CCN(CC)CN(CC)CC UNEXJVCWJSHFNN-UHFFFAOYSA-N 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridine hydrochloride Substances [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims 2
- -1 2-carboxychromon-5-yloxy Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 206010010741 Conjunctivitis Diseases 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QSRWRFJGUJWCTI-UHFFFAOYSA-N 5-[2-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OC(O)(C)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 QSRWRFJGUJWCTI-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB11390/77A GB1582362A (en) | 1977-03-17 | 1977-03-17 | Cromoglycic acid salts and compositions |
| BE185891A BE864837A (fr) | 1977-03-17 | 1978-03-13 | Composition antiallergique |
| IL54264A IL54264A (en) | 1977-03-17 | 1978-03-13 | Pharmaceutical compositions comprising 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol and h1 anti-histamines |
| FI780782A FI780782A7 (fi) | 1977-03-17 | 1978-03-13 | Komposition |
| DE19782810974 DE2810974A1 (de) | 1977-03-17 | 1978-03-14 | Ein salz von 1,3-bis-(2-carboxychromon-5-yloxy)-propan-2-ol und seine verwendung |
| DK113378A DK113378A (da) | 1977-03-17 | 1978-03-14 | Fremgangsmaade til fremstilling af salte af 1,3-bis (2-carxychromon-5-yloxy)propan-2-ol. |
| ZA00781520A ZA781520B (en) | 1977-03-17 | 1978-03-15 | Anti-histamine salts and mixtures |
| IE530/78A IE46581B1 (en) | 1977-03-17 | 1978-03-15 | Cromoglycic acid salts and compositions |
| FR7807669A FR2383937A1 (fr) | 1977-03-17 | 1978-03-16 | Composition antiallergique contenant au moins un sel de 1,3-bis (2-carboxychromone-5-yloxy) propane-2-ol |
| CA299,237A CA1113862A (en) | 1977-03-17 | 1978-03-16 | Mixtures of 1,3-bis(2-carboxy-chromon-5-yloxy) propan- 2-ol or a salt thereof with an antihistamine having h.sub.1 receptor antagonist properties |
| NL7802869A NL7802869A (nl) | 1977-03-17 | 1978-03-16 | Anti-histamine-stoffen en preparaten die ze be- vatten. |
| NZ186712A NZ186712A (en) | 1977-03-17 | 1978-03-16 | Salts of 1,3-bis-(2-carboxychromon-5-yloxyd-propan-2-ol with basic antihistamine compounds mixtures of salts of 1,3-(2-carboxychromon-5-yloxy)propan-2-ol and basic antihistamine compounds |
| SE7803069A SE444939B (sv) | 1977-03-17 | 1978-03-16 | Forfarande for framstellning av en antiallergiskt verksam blandning av 1,3-bis(2-karboxikromon-5-yloxi)propan-2-ol och antihistamin |
| CH289578A CH628517A5 (en) | 1977-03-17 | 1978-03-16 | Anti-allergic medicament |
| LU79253A LU79253A1 (fr) | 1977-03-17 | 1978-03-16 | Composition antiallergique et procede de preparation |
| NO780935A NO152297C (no) | 1977-03-17 | 1978-03-16 | Analogifremgangsmaate for fremstilling av et terapeutisk aktivt salt av 1,3-bis(2-karboksykromon-5-yloksy)-propan-2-ol med et antihistamin |
| IT2128378A IT1158667B (it) | 1977-03-17 | 1978-03-16 | Sali e miscele di 1,3-bis(2-carbossicromon-5-ilossi) propan-2-olo o suoi sali con anti-istaminici ad attivita' di antagonisti di ricettore h1 |
| JP3002278A JPS53115823A (en) | 1977-03-17 | 1978-03-17 | Salt of chromon derivative and antiihistamine agent and mixture |
| AU34272/78A AU516337B2 (en) | 1977-03-17 | 1978-03-17 | Salts of 1, 3-bis(2-carboxychromon-5-yloxy)propan-2-ol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB11390/77A GB1582362A (en) | 1977-03-17 | 1977-03-17 | Cromoglycic acid salts and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1582362A true GB1582362A (en) | 1981-01-07 |
Family
ID=9985349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB11390/77A Expired GB1582362A (en) | 1977-03-17 | 1977-03-17 | Cromoglycic acid salts and compositions |
Country Status (18)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0040489A1 (en) * | 1980-05-17 | 1981-11-25 | FISONS plc | Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA812811B (en) * | 1980-04-30 | 1982-06-30 | Fisons Ltd | Mixtures and salts of beta-2 selective bronchodilators with cromoglycic acid and salts thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL44022A0 (en) * | 1973-01-23 | 1974-05-16 | Fisons Ltd | Novel salts of anti-inflammatory quinoline derivatives,their preparation and pharmaceutical compositions containing them |
| FR2217004A1 (en) * | 1973-02-15 | 1974-09-06 | Aries Robert | Sedatives and bronchodilatories - i.e. salts of 1,3-bis(2-carboxychromon-5-yloxy)propanes with 3-hydroxy-2-hydroxymethyl pyridines |
| FR2230358A2 (en) * | 1973-05-25 | 1974-12-20 | Fisons Ltd | Cromoglycate contg. solns. - contg. a second therapeutically active cpd. e.g. an antihistamine |
| DE2535258C2 (de) * | 1974-08-10 | 1993-06-03 | Fisons Plc, Ipswich, Suffolk | Inhalierbares Medikament in Pelletform |
-
1977
- 1977-03-17 GB GB11390/77A patent/GB1582362A/en not_active Expired
-
1978
- 1978-03-13 BE BE185891A patent/BE864837A/xx not_active IP Right Cessation
- 1978-03-13 IL IL54264A patent/IL54264A/xx unknown
- 1978-03-13 FI FI780782A patent/FI780782A7/fi not_active Application Discontinuation
- 1978-03-14 DE DE19782810974 patent/DE2810974A1/de active Granted
- 1978-03-14 DK DK113378A patent/DK113378A/da not_active Application Discontinuation
- 1978-03-15 ZA ZA00781520A patent/ZA781520B/xx unknown
- 1978-03-15 IE IE530/78A patent/IE46581B1/en not_active IP Right Cessation
- 1978-03-16 CH CH289578A patent/CH628517A5/fr not_active IP Right Cessation
- 1978-03-16 CA CA299,237A patent/CA1113862A/en not_active Expired
- 1978-03-16 FR FR7807669A patent/FR2383937A1/fr active Granted
- 1978-03-16 SE SE7803069A patent/SE444939B/sv not_active IP Right Cessation
- 1978-03-16 NL NL7802869A patent/NL7802869A/xx not_active Application Discontinuation
- 1978-03-16 LU LU79253A patent/LU79253A1/xx unknown
- 1978-03-16 NO NO780935A patent/NO152297C/no unknown
- 1978-03-16 NZ NZ186712A patent/NZ186712A/xx unknown
- 1978-03-17 JP JP3002278A patent/JPS53115823A/ja active Pending
- 1978-03-17 AU AU34272/78A patent/AU516337B2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0040489A1 (en) * | 1980-05-17 | 1981-11-25 | FISONS plc | Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine |
Also Published As
| Publication number | Publication date |
|---|---|
| NO152297C (no) | 1985-09-04 |
| IL54264A (en) | 1984-01-31 |
| DE2810974A1 (de) | 1978-09-21 |
| AU3427278A (en) | 1979-09-20 |
| DE2810974C2 (enrdf_load_stackoverflow) | 1988-07-21 |
| CA1113862A (en) | 1981-12-08 |
| IL54264A0 (en) | 1978-06-15 |
| BE864837A (fr) | 1978-09-13 |
| ZA781520B (en) | 1979-04-25 |
| NL7802869A (nl) | 1978-09-19 |
| JPS53115823A (en) | 1978-10-09 |
| CH628517A5 (en) | 1982-03-15 |
| NO780935L (no) | 1978-09-19 |
| SE7803069L (sv) | 1978-09-18 |
| FR2383937B1 (enrdf_load_stackoverflow) | 1982-07-23 |
| IE46581B1 (en) | 1983-07-27 |
| NZ186712A (en) | 1979-12-11 |
| FI780782A7 (fi) | 1978-09-18 |
| FR2383937A1 (fr) | 1978-10-13 |
| LU79253A1 (fr) | 1978-10-17 |
| IE780530L (en) | 1978-09-17 |
| SE444939B (sv) | 1986-05-20 |
| NO152297B (no) | 1985-05-28 |
| AU516337B2 (en) | 1981-05-28 |
| DK113378A (da) | 1978-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100211479B1 (ko) | 3-[2-(디메틸아미노)에틸]-n-메틸-1h-인돌-5-메탄술폰아미드의 비강 투여 제제 | |
| US5561149A (en) | Use of certain imidazol carbazols in treating stress-related manic-depressive disorders | |
| AU613107B2 (en) | Azelastine-containing medicaments for application in the nose and/or at the eye | |
| CZ290987B6 (cs) | Oční přípravek se sníľenou viskozitou | |
| US20020037297A1 (en) | Process for the topical treatment of rhinitis, conjunctivitis cold, and cold-like and flu symptoms | |
| US20090325948A1 (en) | Inhibitors of undecaprenyl pyrophosphate synthase | |
| US20060228306A1 (en) | Combination antihistamine and steroid medication | |
| CZ283693A3 (en) | Antiallergic preparations for use in ophthalmology and otorhinology | |
| CA2822683A1 (en) | Bepotastine compositions | |
| US4053628A (en) | Composition | |
| KR20150020301A (ko) | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 | |
| RU2561871C2 (ru) | Антагонист опиоидных рецепторов (налтрексон) для использования в терапии герпесного опоясывающего лишая | |
| US3975536A (en) | Composition | |
| US4385048A (en) | Methods for the treatment of nasal hypersecretion | |
| CA1113862A (en) | Mixtures of 1,3-bis(2-carboxy-chromon-5-yloxy) propan- 2-ol or a salt thereof with an antihistamine having h.sub.1 receptor antagonist properties | |
| JPH11189533A (ja) | 点眼薬 | |
| CN101491532B (zh) | 灯盏细辛酚眼用制剂及其制备方法 | |
| RU2100020C1 (ru) | Средство для местного лечения глазной гипертензии и глаукомы и способ его получения | |
| JPS588013A (ja) | 緑内障および高眼圧症の治療用薬学的調合物 | |
| EP0577913A1 (en) | Pharmaceutical preparation | |
| CA2083611A1 (en) | Use of platelet activating factor antagonists as anti-pruritic agents | |
| JPH05221873A (ja) | 鼻および目に局所使用するためのブラジキニン拮抗剤含有薬学的組成物 | |
| CA1131131A (en) | Preparation for the treatment of nasal hypersecretion | |
| CA2058249A1 (en) | Substituted pyridine derivatives for use in the treatment of glaucoma | |
| WO2022232602A1 (en) | Stable isoquinoline-corticosteroid conjugates and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 704A | Declaration that licence is not available as of right for an excepted use (par. 4a/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19970303 |